Literature DB >> 11573595

Propofol inhibits FMLP-stimulated phosphorylation of p42 mitogen-activated protein kinase and chemotaxis in human neutrophils.

T Nagata1, M Kansha, K Irita, S Takahashi.   

Abstract

Propofol is used in the peri-operative setting and may affect some neutrophil functions. The effects of propofol on the function and intracellular signal transduction systems of neutrophils is controversial. Mitogen-activated protein kinase families (MAPKs) are members of the intracellular signal-transducing systems in eukaryotes. MAPKs have been shown to be involved in neutrophil chemotaxis by the use of PD98059, the specific inhibitor of MAPK/ERK kinase (MEK). The effects of propofol in dimethyl sulfoxide on phosphorylation of MAPKs and chemotaxis were investigated in human neutrophils. Isolated neutrophils (2 x 10(7) cells per ml) from healthy volunteers were incubated with propofol (2-500 microM) and stimulated by N-formyl-L-methionyl-phenylalanine (FMLP) (100 nM). The effects of propofol on the phosphorylation of p44/42 MAPK were investigated by immunoblotting. The effects of FMLP (1 microM) on chemotaxis were investigated with the under-agarose method. The phosphorylation of p42 MAPK and chemotaxis stimulated by FMLP were both inhibited by propofol at clinically relevant concentrations (> or = 10 and > or = 20 microM respectively). PD98059 (50 microM) also inhibited chemotaxis stimulated by FMLP, suggesting the involvement of p42 MAPK in the response. Propofol might therefore inhibit human neutrophil chemotaxis, at least in part, by suppressing the p44/42 MAPK pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11573595     DOI: 10.1093/bja/86.6.853

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  9 in total

Review 1.  Anesthetics, immune cells, and immune responses.

Authors:  Shin Kurosawa; Masato Kato
Journal:  J Anesth       Date:  2008-08-07       Impact factor: 2.078

2.  Ketamine reduces inducible superoxide generation in human neutrophils in vitro by modulating the p38 mitogen-activated protein kinase (MAPK)-mediated pathway.

Authors:  Huang-Wei Lu; Guan-Nan He; Hong Ma; Jun-Ke Wang
Journal:  Clin Exp Immunol       Date:  2010-03-16       Impact factor: 4.330

3.  Sedative drug modulates T-cell and lymphocyte function-associated antigen-1 function.

Authors:  Koichi Yuki; Sulpicio G Soriano; Motomu Shimaoka
Journal:  Anesth Analg       Date:  2011-03-08       Impact factor: 5.108

4.  Propofol Ameliorates Exaggerated Human Neutrophil Activation in a LPS Sepsis Model.

Authors:  Andre Bredthauer; Angela Geiger; Michael Gruber; Sophie-Marie Pfaehler; Walter Petermichl; Diane Bitzinger; Thomas Metterlein; Timo Seyfried
Journal:  J Inflamm Res       Date:  2021-08-11

5.  Propofol attenuates lipopolysaccharide-induced monocyte chemoattractant protein-1 production through p38 MAPK and SAPK/JNK in alveolar epithelial cells.

Authors:  Liguo Wei; Hiroko Matsumoto; Hidenori Yamaguchi
Journal:  J Anesth       Date:  2012-12-21       Impact factor: 2.078

6.  Effect of propofol on adhesion of activated platelets to leukocytes in human whole blood.

Authors:  Lothar de Rossi; Martina Wessiepe; Wolfgang Buhre; Ralf Kuhlen; Gabriele Hutschenreuter; Rolf Rossaint
Journal:  Intensive Care Med       Date:  2003-06-11       Impact factor: 17.440

Review 7.  Immunomodulatory effects of anesthetics in obese patients.

Authors:  Luciana Boavista Barros Heil; Pedro Leme Silva; Paolo Pelosi; Patricia Rieken Macedo Rocco
Journal:  World J Crit Care Med       Date:  2017-08-04

8.  Propofol specifically suppresses IL-1β secretion but increases bacterial survival in Staphylococcus aureus-infected RAW264.7 cells.

Authors:  Ming-Shan Chen; Wen-Chun Lin; Hsuan-Te Yeh; Chia-Lin Hu; Shew-Meei Sheu
Journal:  Mol Cell Biochem       Date:  2018-04-17       Impact factor: 3.396

Review 9.  Anesthetic Strategies in Oncological Surgery: Not Only a Simple Sleep, but Also Impact on Immunosuppression and Cancer Recurrence.

Authors:  Federico Longhini; Andrea Bruni; Eugenio Garofalo; Rosalba De Sarro; Riccardo Memeo; Paolo Navalesi; Giuseppe Navarra; Girolamo Ranieri; Giuseppe Currò; Michele Ammendola
Journal:  Cancer Manag Res       Date:  2020-02-10       Impact factor: 3.989

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.